Ohtuvayre ensifentrine

Drug Class

Inhaled dual phosphodiesterase 3 and 4 (PDE3/PDE4) inhibitor

Mechanism

Ensifentrine acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), exerting both bronchodilator and anti-inflammatory effects in the airways.

Approved Indication

Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

What This Means For Patients

Ohtuvayre is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2024) — Sources

Pivotal Clinical Evidence

• ENHANCE-1 — Anzueto et al., Am J Respir Crit Care Med 2023 (NCT04535986) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218698s000lbl.pdf
• https://doi.org/10.1164/rccm.202306-0944OC